Buy Zyceva : Erlotinib 100 mg Tablet 30’S Online

Description

Description: Zyceva is a medication manufactured by Zydus Oncosciences. It contains the active substance erlotinib in each tablet. Each package contains 30 tablets, each containing 100 milligrams of erlotinib. Zyceva belongs to a class of medications known as epidermal growth factor receptor (EGFR) inhibitors and is primarily used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer.

Active Substance: The active substance in Zyceva is erlotinib. Erlotinib inhibits the activity of the epidermal growth factor receptor (EGFR), a protein that is overexpressed in certain types of cancer cells, including NSCLC and pancreatic cancer. By blocking EGFR signaling, erlotinib helps slow down the growth and spread of cancer cells.

Indications: Zyceva is indicated for the treatment of:

• Non-small cell lung cancer (NSCLC): It is used as a first-line treatment in patients with metastatic NSCLC whose tumors have certain EGFR mutations.
• Pancreatic cancer: It is used in combination with gemcitabine for the treatment of locally advanced, unresectable, or metastatic pancreatic cancer.

Mechanism of Action:

• Erlotinib inhibits the activity of the epidermal growth factor receptor (EGFR), a transmembrane protein that plays a key role in cell growth and proliferation.
• By blocking EGFR signaling, erlotinib interferes with cancer cell growth and survival, leading to inhibition of tumor growth and spread.
• Erlotinib may also have anti-angiogenic properties, meaning it can inhibit the formation of new blood vessels that supply nutrients to the tumor, further slowing tumor growth.

Administration:

• Zyceva tablets are taken orally with water, usually once daily.
• The tablets should be swallowed whole and should not be crushed, chewed, or broken.
• It is recommended to take Zyceva tablets at the same time each day, with or without food, as directed by the healthcare provider.

Dosage:

• The recommended dosage of Zyceva is one 100-milligram tablet taken orally once daily.
• Treatment duration and dosage adjustments may be made based on the patient’s response to treatment and tolerability.

Monitoring:

• Patients taking Zyceva should be monitored regularly by their healthcare provider to assess treatment response, monitor for any signs of adverse effects, and adjust dosage as necessary.
• Monitoring may include imaging studies, laboratory tests, and clinical assessments.

Side Effects: Common side effects of erlotinib may include:

• Rash
• Diarrhea
• Fatigue
• Loss of appetite
• Nausea and vomiting
• Mouth sores
• Dry skin
• Conjunctivitis (inflammation of the eyes)

Precautions:

• Zyceva should be used with caution in patients with pre-existing liver or kidney disease, as well as in patients with a history of interstitial lung disease or other pulmonary disorders.
• It is important to inform the healthcare provider about all medications, supplements, and herbal products being taken, as erlotinib may interact with certain medications.
• Women who are pregnant or breastfeeding should not take Zyceva, as it may cause harm to the fetus or infant.

Consultation with Healthcare Professional:

• The use of Zyceva should be discussed with a qualified healthcare professional, typically an oncologist or specialist in the specific type of cancer being treated.
• Patients should inform their healthcare provider about their medical history, existing health conditions, and any medications they are taking before starting treatment with erlotinib.

Zyceva, manufactured by Zydus Oncosciences, is a medication indicated for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Its use involves careful adherence to dosage and instructions for use, as well as regular monitoring by a healthcare provider to assess treatment response and monitor for any adverse effects or complications.